These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21575929)

  • 61. Platelet mass has prognostic value in patients with myelodysplastic syndromes.
    Bowles KM; Warner BA; Baglin TP
    Br J Haematol; 2006 Oct; 135(2):198-200. PubMed ID: 16939490
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Aberrant increase in the immature platelet fraction in patients with myelodysplastic syndrome: a marker of karyotypic abnormalities associated with poor prognosis.
    Sugimori N; Kondo Y; Shibayama M; Omote M; Takami A; Sugimori C; Ishiyama K; Yamazaki H; Nakao S
    Eur J Haematol; 2009 Jan; 82(1):54-60. PubMed ID: 18801060
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Serum ferritin is an independent prognostic factor in Chinese with myelodysplastic syndromes classified as IPSS Intermediate-1.
    Li B; Xu Z; Gale RP; Qin T; Zhang Y; Xiao Z
    Acta Haematol; 2013; 129(4):243-50. PubMed ID: 23328695
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases.
    Wattel E; Cambier N; Caulier MT; Sautière D; Bauters F; Fenaux P
    Br J Haematol; 1994 May; 87(1):205-8. PubMed ID: 7947249
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience.
    Grabska J; Shah B; Reed D; Al Ali N; Padron E; Ramadan H; Lancet J; List A; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S53-6. PubMed ID: 27521325
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
    Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
    Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Influence of TNF and IL6 gene polymorphisms on the severity of cytopenias in Argentine patients with myelodysplastic syndromes.
    Bestach Y; Nagore VP; Flores MG; González J; Arbelbide J; Watman N; Sieza Y; Larripa I; Belli C
    Ann Hematol; 2017 Aug; 96(8):1287-1295. PubMed ID: 28601896
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
    Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
    Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes.
    Sandes AF; Yamamoto M; Matarraz S; Chauffaille Mde L; Quijano S; López A; Oguro T; Kimura EY; Orfao A
    Haematologica; 2012 Jun; 97(6):895-902. PubMed ID: 22271903
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
    Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
    Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
    Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
    Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
    Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
    Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Etiology and clinical characteristics of pregnancy-emerged thrombocytopenia].
    Chen Z; Liang MY; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2011 Nov; 46(11):834-9. PubMed ID: 22333233
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.
    Zeidan AM; Lee JW; Prebet T; Greenberg P; Sun Z; Juckett M; Smith MR; Paietta E; Gabrilove J; Erba HP; Katterling RP; Tallman MS; Gore SD
    Br J Haematol; 2014 Oct; 167(1):62-8. PubMed ID: 24995683
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A prognostic score for patients with lower risk myelodysplastic syndrome.
    Garcia-Manero G; Shan J; Faderl S; Cortes J; Ravandi F; Borthakur G; Wierda WG; Pierce S; Estey E; Liu J; Huang X; Kantarjian H
    Leukemia; 2008 Mar; 22(3):538-43. PubMed ID: 18079733
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes.
    Ma X; Wang R; Galili N; Mayne ST; Wang SA; Yu H; Raza A
    Cancer Causes Control; 2011 Apr; 22(4):623-9. PubMed ID: 21287258
    [TBL] [Abstract][Full Text] [Related]  

  • 79. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.
    Gyan E; Andrieu V; Sanna A; Caille A; Schemenau J; Sudaka I; Siguret V; Malet M; Park S; Bordessoule D; Mairesse J; Gelsi-Boyer V; Cheze S; Beyne-Rauzy O; Sébert M; Sapena R; Zerazhi H; Legros L; Guerci-Bresler A; Amé SN; Germing U; Santini V; Salvi F; Gioia D; Lunghi M; Dreyfus F; Fenaux P;
    Br J Haematol; 2016 Dec; 175(5):975-979. PubMed ID: 26773632
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.